GRN and neurodegenerative disease: One advantage in the pursuit of progranulin-targeted therapeutics is that, unlike amyloid-beta, tau, and other proteins associated with neurodegenerative diseases that have gain-of-function effects, the mechanism of progranulin-related disease is clearly loss-of-function.